CD200 and cancer: Overall, the inconsistent response rates across different tumor types, low incidence of durable responses and observed undesirable cytotoxicity outcomes to samalizumab therapy together with newly emerging non-canonical roles for CD200 in cancer provides rationale for alternative strategies designed to efficaciously target this protein.